September 13, 2018 02:51 PM EDT
Pharma

As­traZeneca grabs an FDA OK for its new leukemia drug, to be mar­ket­ed as Lu­mox­i­ti

John Carroll

Editor & Founder

As­traZeneca $AZN just got an­oth­er boost for its on­col­o­gy port­fo­lio. The FDA has whisked through a fast OK for the an­ti-CD22 drug mox­e­tu­momab pa­su­do­tox for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times